You are here

Our science / Clinical Trials / Find a Trial / NCT00143143

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Back to Search Print Save as PDF Bookmark Trial

NCT00143143

Last updated on May 12, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Innsbruck, , A6020 Austria
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsies, Complex Partial Epilepsy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must have met the inclusion criteria for Study 1008-157, have received
double-blind study medication, and wish to receive open-label pregabalin

- Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial
seizures during the 6 weeks prior to screening

- Be currently taking 1 to 3 AEDs.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Have a treatable cause of seizures

- Experienced a serious adverse event during Study 1008-157 which was determined to be
possibly related to study medication

NCT00143143
Pfizer
Completed
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Partial Seizures Epilepsy, Primary Generalized Tonic-Clonic Seizures Epilepsy
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306
All Genders
0+
Years
Multiple Sites
Partial Epilepsies
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611
All Genders
18+
Years
Multiple Sites
Partial Onset Seizures
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
NCT02072824
All Genders
0+
Years
Multiple Sites
Partial Epilepsies, Complex Partial Epilepsy
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
NCT00143143
All Genders
18+
Years
Multiple Sites
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
Pregabalin BID Open-Label Add-On Trial: A Follow-Up Study To Determine Long-Term Safety and Efficacy in Patients With Partial Seizures
The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Epilepsies, Partial
  • Epilepsy, Complex Partial
Drug: Pregabalin
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
February 2006
Not Provided

Inclusion Criteria:

  • Patients must have met the inclusion criteria for Study 1008-157, have received double-blind study medication, and wish to receive open-label pregabalin
  • Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening
  • Be currently taking 1 to 3 AEDs.

Exclusion Criteria:

  • Have a treatable cause of seizures
  • Experienced a serious adverse event during Study 1008-157 which was determined to be possibly related to study medication
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Canada,   France,   Germany,   Italy,   Lithuania,   Spain,   United Kingdom
 
 
NCT00143143
1008-000-164
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2006

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now